SYRE on Nasdaq
Aeglea BioTherapeutics
Business enterprise in United States of America.1
Price unavailable
Last updated Oct 16, 2026.
Overview
Jan 1, 2013Founded1
Compare with Corbus Pharmaceuticals, Rallybio or Neurogene Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-21.7%Return on equity4
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenue | $0 | $0 | $886.0K |
| Acquired in-process research and development | $0 | $0 | $130.2M |
| Gain on sale of in-process research and development asset | -$10.0M | $0 | -$16.4M |
| Total operating expenses | $209.6M | $208.6M | $243.2M |
| Loss from operations | -$209.6M | -$208.6M | -$242.3M |
| Interest income | $24.9M | $21.3M | $6.1M |
| Other income (expense), net | $29.5M | -$20.7M | -$19.1M |
| Total other income (expense) | $54.3M | $599.0K | -$96.5M |
| Loss before income tax expense | -$155.2M | -$208.0M | -$338.8M |
| Income tax benefit (expense) | $15.0K | -$51.0K | $26.0K |
| Net loss | -$155.2M | -$208.0M | -$338.8M |
| Research and development | $171.7M | $162.8M | $89.5M |
| General and administrative | $47.9M | $45.8M | $39.9M |
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $85.7M | $89.4M | $188.9M |
| Marketable securities | $670.8M | $513.7M | |
| Prepaid expenses and other current assets | $21.2M | $5.4M | |
| Total current assets | $777.8M | $608.5M | |
| Other non-current assets | $0 | $10.0K | |
| TOTAL ASSETS | $777.8M | $608.5M | |
| CVR liability | $22.8M | $25.1M | |
| Accrued and other current liabilities | $26.9M | $27.7M | |
| Total current liabilities | $58.7M | $54.1M | |
| Non-current CVR liability | $3.9M | $36.6M | |
| TOTAL LIABILITIES | $62.5M | $90.7M | |
| Common stock, $0.0001 par value; 400,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 78,189,811 shares and 60,257,023 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively. | $15.0K | $13.0K | |
| Additional paid-in capital | $1.7B | $1.3B | |
| Accumulated other comprehensive income | $869.0K | $180.0K | |
| Accumulated deficit | -$1.1B | -$972.4M | |
| TOTAL CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS EQUITY | $715.2M | $517.8M | $184.0M |
| TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS EQUITY | $777.8M | $608.5M | |
| Convertible preferred stock, par value (in dollars per share) | $0.00 | ||
| Convertible preferred stock, authorized (in shares) | 10.0M shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, authorized (in shares) | 400.0M shares | 400.0M shares | |
| Common stock, issued (in shares) | 78.2M shares | 60.3M shares | |
| Common stock, outstanding (in shares) | 78.2M shares | 60.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$155.2M | -$208.0M | -$338.8M |
| Depreciation and amortization | $0 | $0 | $744.0K |
| Stock-based compensation | $37.6M | $44.8M | $25.7M |
| Acquired in-process research and development | $0 | $0 | $130.2M |
| Gain on sale of in-process research and development asset | -$10.0M | $0 | -$16.4M |
| Lease ROU asset and leasehold improvement impairment loss | $0 | $0 | $2.6M |
| Loss on disposal of long-lived assets | $0 | $0 | $915.0K |
| Net (accretion of discount) amortization of premium on marketable securities | -$8.1M | -$11.4M | -$2.3M |
| Interest proceeds from maturities of zero coupon debt securities | $2.1M | $1.3M | $0 |
| Amortization of operating lease assets | $0 | $0 | $220.0K |
| Other | $0 | $0 | $15.0K |
| Prepaid expenses and other assets | -$12.8M | -$2.9M | $3.2M |
| Accounts payable | $8.2M | -$230.0K | $218.0K |
| Deferred revenue | $0 | $0 | $575.0K |
| Development receivables | $0 | $0 | $375.0K |
| Operating lease liabilities | $0 | $0 | -$2.3M |
| Accrued and other liabilities | -$764.0K | $14.6M | -$4.9M |
| Related party accounts payable | -$589.0K | -$16.0M | -$2.4M |
| Net cash used in operating activities | -$169.3M | -$157.4M | -$99.9M |
| Cash assumed from asset acquisition of Spyre | $0 | $0 | $3.0M |
| Proceeds from sale of in-process research & development asset | $7.0M | $0 | $15.0M |
| Proceeds from the sale of property plant and equipment | $0 | $0 | $475.0K |
| Purchases of marketable securities | -$522.2M | -$599.3M | -$166.8M |
| Proceeds from maturities and sales of marketable securities | $371.7M | $246.0M | $39.9M |
| Net cash (used in) provided by investing activities | -$143.5M | -$353.3M | -$108.4M |
| Proceeds from issuance of common stock in connection with at-the-market offering program, net of issuance costs | $14.8M | $20.5M | $0 |
| Proceeds from issuance of common stock in connection with follow-on offering, net of issuance costs | $296.4M | $215.9M | $0 |
| Payment of deferred offering costs in connection with shelf registration | -$162.0K | -$407.0K | $0 |
| Payment of contingent value rights liability | -$5.3M | -$1.4M | -$5.8M |
| Proceeds from employee stock option exercises and employee stock plan purchases | $3.3M | $7.5M | $405.0K |
| Other financing cash flows | $0 | $1.0K | -$16.0K |
| Net cash provided by financing activities | $309.0M | $410.9M | $361.1M |
| Effect of exchange rate on cash, cash equivalents, and restricted cash | $0 | -$3.0K | $25.0K |
| NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | -$3.7M | -$99.8M | $152.8M |
| Allocation of deferred offering costs against proceeds of issuance of common stock | $107.0K | $204.0K | $0 |
| Settlement of forward contract liability and issuance of Series A non-voting convertible preferred stock in connection with the asset acquisition of Spyre | $0 | $0 | $189.7M |
Former names
- Aeglea BioTherapeutics, Inc.Mar 24, 2015 to Nov 24, 20233
Timeline
- Jan 1, 2013Founded Founded1
Recent filings
- Oct 9, 2026SCHEDULE 13D/A
- Oct 7, 20268-K
- Oct 6, 2026424B5
- Oct 5, 2026424B5
- Oct 2, 20264
- Oct 2, 20264
- Oct 2, 20264
- Oct 1, 2026SCHEDULE 13G
- Oct 1, 2026144
- Oct 1, 2026144
- Sep 30, 2026144
- Sep 8, 20268-K
- Sep 3, 20264
- Sep 3, 20264
- Sep 3, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websiteaegleabio.com1
- WikidataQ45133036
- SEC EDGARCIK 1636282
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11